Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

29 Jun 2023 13:35

RNS Number : 4207E
Advanced Oncotherapy PLC
29 June 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BD6SX109

Issuer Name

ADVANCED ONCOTHERAPY PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights; An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

ODEY ASSET MANAGEMENT LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

28-Jun-2023

6. Date on which Issuer notified

29-Jun-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

7.490000

10.630000

18.120000

97973508

Position of previous notification (if applicable)

9.140000

10.680000

19.820000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BD6SX109

40473508

0

7.490000

0.000000

Sub Total 8.A

40473508

7.490000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Warrant

1 July 2026

Cash

18000000

3.330000

Warrant

30 march 2026

Cash

8000000

1.480000

Warrant

31 OCTOBER 2027

Cash

24000000

4.440000

Warrant

25 February 2025

Cash

7500000

1.390000

Sub Total 8.B2

57500000

10.630000%

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

none

12. Date of Completion

29-Jun-2023

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUKOUROOUNUAR
Date   Source Headline
4th Jul 20189:00 amRNSPrice Monitoring Extension
2nd Jul 20187:00 amRNSDirectorate Changes
27th Jun 20187:00 amRNSFinal Results
31st May 20187:00 amRNSUpdate on financing
29th May 20187:00 amRNSTechnological update
11th May 20184:35 pmRNSPrice Monitoring Extension
11th May 20187:00 amRNSUpdate on Distribution Agreement Payment
8th May 20187:00 amRNSUK assembly and testing site agreement
26th Apr 20181:50 pmRNSGPSL Research on Advanced Oncotherapy Plc
5th Apr 20187:00 amRNSHolding(s) in Company
3rd Apr 20189:43 amRNSUpdate on Distribution Agreement
12th Mar 20187:15 amRNSHardman & Co Research: Confidence greatly boosted
23rd Feb 20184:05 pmRNSHolding(s) in Company
16th Feb 20187:00 amRNSCompletion of the Subscription Agreement
23rd Jan 201811:48 amRNSResult of Meeting
12th Jan 20187:00 amRNSDirector dealing
28th Dec 20177:01 amRNSNotice of GM
28th Dec 20177:00 amRNSTechnological update
22nd Dec 201711:24 amRNSHolding(s) in Company
13th Dec 20174:25 pmRNSHolding(s) in Company
11th Dec 20172:02 pmRNSHardman Res.: Distribution deal & capital increase
7th Dec 20177:00 amRNSDistribution agreement and Equity Investments
29th Sep 20177:00 amRNSHalf-year Report
4th Sep 20177:00 amRNSTechnological update
1st Aug 20177:00 amRNSDirector Dealing
31st Jul 20177:00 amRNSTechnological milestones update - CCL units
19th Jul 20173:56 pmRNSResult of AGM
19th Jul 201710:16 amRNSFinancing facility by significant shareholders
5th Jul 20177:00 amRNSVideo and update on progress at Harley Street
26th Jun 20177:00 amRNSFinal Results
21st Jun 20177:00 amRNSConversion of Convertible Loan Notes
14th Jun 20177:00 amRNSAppointment of Senior VP of Medical Physics
13th Jun 20177:00 amRNSAdditional financing agreement and new appointment
12th Jun 20177:00 amRNSTechnological milestones update
5th Jun 20172:45 pmRNSUpdate on Bracknor financing
31st May 20174:41 pmRNSHolding(s) in Company
30th May 20177:00 amRNSHarley Street construction update
26th May 20176:23 pmRNSConversion of Convertible Loan Notes
26th May 20177:00 amRNSUpdate on Bracknor financing
24th May 20177:13 amRNSConversion of convertible loan notes
23rd May 201712:01 pmRNSHolding(s) in Company
18th May 20177:31 amRNSConversion of convertible loan notes
16th May 20179:02 amRNSConversion of loan notes
15th May 20171:01 pmRNSDirector Dealing
11th May 20177:00 amRNSDirector Dealing
8th May 20177:00 amRNSIssue of Equity & Director Shareholding
4th May 20177:05 amRNSHolding(s) in Company
3rd May 20171:29 pmRNSHolding(s) in Company
28th Apr 20177:00 amRNSUpdate on Bracknor financing
26th Apr 201711:18 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.